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1. Introduction 
1.1 Background 
Peptic ulcer disease (PUD) had a tremendous effect on morbidity and mortality until the last 
decades of the 20th century. Development of new effective and potent acid suppressants and 
the discovery of Helicobacter pylori (H. pylori) are two important steps that caused a 
reduction in the prevalence of peptic ulcer. With the discovery of H. pylori, causes, 
pathogenesis and treatment of PUD have been defined again in the last 25 years. However, 
this condition continues to be an important clinical issue because of common use of 
nonsteroidal anti-inflammatory drugs (NSAID) and acetylsalicylic acid at low doses. The 
rare but increasingly problematic issue is H pylori-negative and NSAID-negative ulcers (1). 
Despite progress in diagnosis and treatment, peptic ulcer disease (PUD) remains a common 
reason for hospitalization and operation (2). 
Peptic ulcer disease (PUD) affects 10% of the world population. Helicobacter pylori infection 
and the use of a nonsteroidal anti-inflammatory drug (NSAID) are the principal factors 
associated with PUD (3). The declining global prevalence of peptic ulcer disease (PUD) 
might be because of the decreasing prevalence of Helicobacter pylori (Hp) infection (4). The 
decreasing prevalence of H. pylori could lead to a relative increase in the number of patients 
with this NSAID associated and idiopathic peptic ulcer disease (IPUD (5). Another view is 
that incidence of peptic ulcers decreased and an increasing proportion was related to 
NSAID and the Mortality was high (6). It is also known that the incidence of idiopathic 
peptic ulcer disease has increased (7,8).  
H pylori infection causes both gastric and duodenal ulcers (35-27). Current data shows that 
H pylori infection plays a major role in peptic ulcer disease and non-ulcer dyspepsia (9,10). 
Apart from these diseases, H pylori are thought to play a role in the etiology of atrophic 
gastritis, gastric adenocarcinoma and lymphoma. In our country, H. pylori prevalence 
remains an important health problem (11). 
The aim of this study is to determine the etiology of patients with duodenal and gastric 
ulcers. 
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2. Materials-methods 
Between April 2002 and April 2009, 140 patients who referred to our endoscopy laboratory 
with dyspeptic complaints for gastroscopy and diagnosed with peptic ulcer (duodenal 
and/or gastric) were enrolled to this prospective study. Before the procedure, medical 
history, cigarette smoking and alcohol consumption and nonsteroidal anti-inflammatory 
drugs (NSAIDs) and acetylsalicylic acid use within the last month were queried. Patients 
with a history of gastric operation, with malign ulcer or another malign disease and who 
were not willing to participate the study were excluded.  
Two biopsy specimens were collected from antrum and corpus for histology and one for 
rapid urease testing and stool samples were analyzed for Helicobacter pylori (H pylori) 
antigen using Laboquick H pylori antigen test kit. A patient was classified as being H. pylori 
positive if any of the three test methods were positive. NSAID and/or acetylsalicylic acid 
use within the last month was associated with ulcer, if any. Inflammatory activity, intestinal 
metaplasia, atrophy and H. pylori were evaluated in histopathological examination. Serum 
calcium and gastrin levels were also analyzed. 
SPSS 13.0 statistical program was used for statistical assessments. Mean ± standard 
deviation (SD) or median were used for quantitative variables. For independent group 
comparisons, intergroup variations were analyzed with non parametrical Mann –Whitney U 
test. Inter group variations were evaluated using Wilcoxon test (for dependent group 
comparison). Correlation analyses were performed using Pearson and Spearman correlation 
tests. Results with “p value” less than 0.05 were accepted as statistically significant. 
3. Results 
82 of the patients (58%) were male and 58% were female (42%). Mean age was 47.70 ± 15.03 
(range 16-92). 62 of the patients (44%) were smoking and 18 (13%) were drinking alcohol. 
132 of the patients (94%) were from urban whereas 8 (6%) were from rural areas. 14 patients 
(10%) had a family history of PUD, whereas 4 (0.3%) had a family history of stomach cancer. 
Ulcer was located in duodenum in 96 patients (69%), in stomach in 40 patients (28%), and 
both in duodenum and stomach in 4 patients (3%).  
Rate of patients tested positive for H pylori antigen in stool, positive in urease testing and 
tested positive for H. pylory presence in antral and corpus samples were 48%, 52%, 67% and 
60% respectively (see Table 1). 107 patients (76%) were positive for H. pylori in one of the 
test methods.  
 
Method Incidence 
Stool sample for H pylori positive  48% 
Rapid urease testing positive 52% 
H pylori positive antral histology  67%  
H pylori positive corpus histology 60%  
H pylori positive with any method 76% 
Table 1. Incidence of H. pylori in peptic ulcer using various methods. 
Among 64 patients (46%) with a story of nonsteroidal antienflammatory drug (NSAID) use 
within the last 1 month, 48 (75%) were Hp positive and 16 were (25%) negative (see Table 2). 
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Mean age of patients on NSAID therapy higher 51.26 ± 15.60 (range 21-92) compared to the 
non-users 45.32 ±14.25 (range 16-80) (p<0.05).  
 
H pylori positive PUD 107 76% 
NSAID use 
       NSAID+H pylori positive 
       NSAİİ+ H pylori 
negatifliği        
64 
          48 
          16 
                (46%) 
                (75%) 
12%         (25%)       
Idiopathic PUD 17 12% 
Table 2. Peptic ulcer (PUD) etiology 
Incidence of inflammatory activity, atrophy and intestinal metaplasia were 65%, 17.5% and 
11% in antral biopsies and 66%, 6.5% and 1.5% in corpus samples, respectively (see Table 2).  
 
 Antrum Corpus
Inlammatory activity 65% 66% 
Atrophy 17.5% 6.5% 
Intestinal metaplasia 11% 1.5% 
H. pylori incidence 67% 60% 
Table 3. Histology findings of the biopsy samples 
Histopathologically inflammatory activity was correlated with H. pylori (p<0.05). Mean 
levels of calcium and gastrin were 9.29 ± 0.40 (7.90-10.20) and 73.96 ± 89.88 (12.86-562.50) 
respectively. In patients with elevated gastrin levels, no hypersecretory condition was 
detected. Elevated levels of gastrin were correlated with inflammatory activity and presence 
of H. pylori (p<0.05).  
19 of patients (13.6%) were negative for H pylori, NSAID use and hypersecretory illness and 
classified as idiopathic. Mean age of these pateints were 51.52 ± 13.88 (range 16-78). Ulcer 
was located in the duodenum of 13 patients (68%) and in stomach of 6 patients (32%). 11 of 
the patients (58%) were male and 8% were female (42%). 9 of the patients (47%) were 
smoking and 3 (16%) were drinking alcohol. 1 patient had a family history of PUD and 1 
had a family history of stomach cancer. Mean age of these patients was higher compared to 
patients with a known etiology (p<0.05), however there were no statistical differences in 
terms of ulcer location, gender, smoking, alcohol consumption, and family history (p>0.5). 
Mean gastrin level of 60.07 ± 64.13 (12.86-183.61) was lower compared to the patients with a 
known etiology (p<0.05) whereas calcium levels of 9.33 ± 0.6 (7.9-10.2) were similar (p>0.5). 
4. Discussion 
54 (19%) of 277 consecutive patients had evidence of peptic ulcer disease (34 gastric ulcer, 14 
duodenal ulcer and 6 both gastric and duodenal ulcer) in a similar study where 
demographic and endoscopic characteristics of patients with Helicobacter pylori positive 
and negative chronic peptic ulcer disease were evaluated (12). The most common finding in 
this study was gastric ulcer whereas in our study, among 140 patients with PUD 96 (69%) 
had duodenal ulcer, 40 had (28%) gastric ulcer and 4 had (3%) both duodenal and gastric 
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ulcer in our study. These variations may be associated with the regional characteristics, 
lower number of patients evaluated in the other study and etiological differences.  
Helicobacter pylori infection and the use of a nonsteroidal anti-inflammatory drug (NSAID) 
are the principal factors associated with PUD (3). Similarly, etiologic factor in 88% of 
patients in our study was H pylori and/or NSAID use.  
While incidence of PUD associated with H pylori infection is decreasing especially in 
western countries (5,7,8), in our country most common cause is H pylori (76%). It may be 
associated with the fact that H. pylori prevalence remains an important health problem in 
our country and prevalence in the community is very high. In a study performed in our 
country with 9239 patients who underwent gastrointestinal endoscopy, H. pylori incidence 
was 41.44% using the CLO test (11).  
In a study where demographic and endoscopic characteristics of peptic ulcer were 
evaluated, urease, culture, histology and serum anti-H pylori IgG antibody were evaluated 
in patients and demographic data as well as NSAID use within the last 3 months were 
assessed. 56% of patients were H pylori positive and 22% were using NSAIDs (70% were H 
pylori positive) (12). In our study H. pylori was evaluated using urease testing, H pylori 
antigen in stool and histology and rate of patients who are H pylori positive and using 
NSAIDs within the last month were higher (76% and 46% respectively). Similarly, some 
patients using NSAID (75%) were also H pylori positive. 
H. pylori induces chronic inflammation of the gastric mucosa, but only a proportion of 
infected individuals develop peptic ulcer disease or gastric carcinoma Reasons underlying 
these observations include differences in bacterial pathogenicity as well as in host 
susceptibility (13). Meta-analyses showed that Helicobacter pylori eradication therapy was 
effective for healing and prevention of recurrence of peptic ulcers in H. pylori-positive 
patients and that treatment of H. pylori infection was more effective than antisecretory non-
eradicating therapy (with or without long-term maintenance therapy) in preventing 
recurrent bleeding (14). H pylori eradication has been associated with decreased risk of 
gastric cancer in patients with peptic ulcer diseases (15). In our study, H pylori were also 
correlated with inflammatory activity. When it is considered that the H pylori associated 
PUD is a common disease in our country, we should give more importance to eradication 
therapy both for effective treatment of PUD and for cancer prophylaxis. 
NSAIDs have known detrimental side effects on the gastrointestinal system. The risk is 
increased with older age and history of PUD. Helicobacter pylori infection and 
cardioprotective acetylsalicylic acid have additive risks in the presence of NSAID use (16). 
The development of PUD was observed earlier in the combined H pylori and NSAID group 
than in patients with only NSAID use and this suggests a synergic effect between the two 
risks factors in the development of PUD (3). In our study, 75% of patients with history of 
NSAID therapy were H pylori positive. This finding suggest that H pylori and NSAID 
usage, when together, increases the risk of PUD. 
Apart from H pylori and NSAID, risk factors such as smoking, alcohol intake, age, and male 
gender were reported as contributing to the gastric and duodenal ulcer development (17-
20). In our study, patients who are supporting these findings were at middle or older age 
and 58% of them were male. Almost half of the patients (44%) were smokers and 13% were 
drinking alcohol.  
Rate of patients classified as idiopathic (H pylori negative, NSAID negative) were reported 
between 4 and 20% (5, 8, 17). Among 140 patients 19 were (13%) H pylori and NSAID 
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negative. Idiopathic ulcer was reported among younger patients in a study (12) where as 19 
patients classified as idiopathic in our study were older compared to patients with a known 
etiology. 
Apart from H pylori, poor socio-economic status has been reported as an important risk 
factor for PUD infection while genetic factors do not influence the risk of PUD (21). 
Although the socio-economic status of the patients enrolled in our study has not been 
investigated in detail, 132 of the patients (94%) were from the urban regions while 8 (6%) 
were from the rural area and 14 (10%) had a history of ulcer. 
As a consequence, most common cause of duodenal and gastric ulcer is H. pylori and is 
responsible for three-fourths of the cases. About half of the patients had a history of NSAID 
use and NSAID and H. pylori are both responsible for the ulcer in three-forths of these 
patients. In one tenth of the patients, NSAİD use was the cause of ulcer alone and about one-
tenth of the ulcers were classified as idiopathic. 
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